Patients taking psilocybin to treat depression show reduced symptoms weeks after treatment following a ‘reset’ of their brain activity.
The findings come from a study in which researchers from Imperial College London used psilocybin – the psychoactive compound that occurs naturally in magic mushrooms – to treat a small number of patients with depression in whom conventional treatment had failed.
In a paper, published in the journal Scientific Reports, the researchers describe patient-reported benefits lasting up to five weeks after treatment, and believe the psychedelic compound may effectively reset the activity of key brain circuits known to play a role in depression.
Comparison of images of patients’ brains before and one day after they received the drug treatment revealed changes in brain activity that were associated with marked and lasting reductions in depressive symptoms.
The authors note that while the initial results of the experimental therapy are exciting, they are limited by the small sample size as well as the absence of a control group – such as a placebo group – to directly contrast with the patients.
Dr Robin Carhart-Harris, Head of Psychedelic Research at Imperial, who led the study, said: “We have shown for the first time clear changes in brain activity in depressed people treated with psilocybin after failing to respond to conventional treatments.
“Several of our patients described feeling ‘reset’ after the treatment and often used computer analogies. For example, one said he felt like his brain had been ‘defragged’ like a computer hard drive, and another said he felt ‘rebooted’.
“Psilocybin may be giving these individuals the temporary ‘kick start’ they need to break out of their depressive states and these imaging results do tentatively support a ‘reset’ analogy. Similar brain effects to these have been seen with electroconvulsive therapy.”
Exploring the potential of psychedelics
Over the last decade or so, a number of clinical trials have been conducted into the safety and effectiveness of psychedelics in patients with conditions such as depression and addictions, yielding promising results.
In the recent Imperial trial, the first with psilocybin in depression, 20 patients with treatment-resistant form of the disorder were given two doses of psilocybin (10 mg and 25 mg), with the second dose a week after the first. Nineteen of these underwent initial brain imaging and then a second scan one day after the high dose treatment.
Carhart-Harris and team used two main brain imaging methods to measure changes in blood flow and the crosstalk between brain regions, with patients reporting their depressive symptoms through completing clinical questionnaires.
Immediately following treatment with psilocybin, patients reported a decrease in depressive symptoms – corresponding with anecdotal reports of an ‘after-glow’ effect characterised by improvements in mood and stress relief.
‘Resetting’ brain activity
Functional MRI imaging revealed reduced blood flow in areas of the brain, including the amygdala, a small, almond-shaped region of the brain known to be involved in processing emotional responses, stress and fear. They also found increased stability in another brain network, previously linked to psilocybin’s immediate effects as well as to depression itself.
Psilocybin may be giving these individuals the temporary ‘kick start’ they need to break out of their depressive states
– Dr Robin Carhart-Harris
These findings provide a new window into what happens in the brains of people after they have ‘come down’ from a psychedelic, where an initial disintegration of brain networks during the drug ‘trip’, is followed by a re-integration afterwards.
Dr Carhart-Harris explained: “Through collecting these imaging data we have been able to provide a window into the after effects of psilocybin treatment in the brains of patients with chronic depression.
“Based on what we know from various brain imaging studies with psychedelics, as well as taking heed of what people say about their experiences, it may be that psychedelics do indeed ‘reset’ the brain networks associated with depression, effectively enabling them to be lifted from the depressed state.”
The authors warn that while the initial findings are encouraging, the research is at an early stage and that patients with depression should not attempt to self-medicate, as the team provided a special therapeutic context for the drug experience and things may go awry if the extensive psychological component of the treatment is neglected.
They add that future studies will include more robust designs and currently plan to test psilocybin against a leading antidepressant in a trial set to start early next year.
The Latest on: Psilocybin
- Santa Cruz Is Third U.S. City To Decriminalize Psilocybin, Plant Medicine, As Advocacy Expandson February 1, 2020 at 1:04 pm
A recent resolution by Santa Cruz City Council has made the municipality the third in the U.S. to decriminalize a wide range of psychedelic plant medicines. The unanimous ruling makes the personal ...
- Study: Psilocybin From Magic Mushrooms Plus Therapy Delivers Benefits Nearly Five Years Lateron January 31, 2020 at 3:29 pm
Following up on a pioneering 2016 study, researchers found a single use of psilocybin combined with therapy sessions resulted in positive psychological effects years later for cancer patients.
- Psilocybin: The magic ingredient in psychedelic shroomson January 29, 2020 at 11:35 am
Reference article: Facts about psilocybin. Psilocybin is the main psychoactive ingredient in hallucinogenic mushrooms, also called "magic mushrooms" or "shrooms." There are over 100 species of ...
- YIELD GROWTH Commends Psilocybin Research Featured in Mainstream Media Including The Goop Lab on Netflix with Gwyneth Paltrowon January 28, 2020 at 7:31 am
Vancouver, British Columbia, Jan 28, 2020 (Newsfile Corp via COMTEX) -- Vancouver, British Columbia--(Newsfile Corp. - January 28, 2020) - The Yield Growth Corp. (CSE ...
- Actress Gwyneth Paltrow Talks Benefits of Psilocybin Mushroomson January 28, 2020 at 6:28 am
Psilocybin, or 'magic' mushrooms may be just what the doctor ordered. It’s become so popular Netflix’s The Goop Lab, starring Gwyneth Paltrow do an entire episode on the psychedelic drug and its ...
- One dose of 'magic mushroom' drug reduces anxiety and depression in cancer patients, study sayson January 28, 2020 at 4:04 am
(CNN)A single dose of psilocybin, a compound found in "magic mushrooms," provides long-term relief of anxiety and depression in cancer patients, a new study finds. In fact, cancer patients who ...
- Psilocybin may help cancer patients with depression and anxiety for yearson January 27, 2020 at 9:11 pm
But the findings leave open the possibility that the compound, called psilocybin, may be able to profoundly reshape how people handle distress and fear (SN: 9/26/06). Research published in 2016 ...
- YIELD GROWTH Commends Psilocybin Research Featured in Mainstream Media Including The Goop Lab on Netflix with Gwyneth Paltrowon January 27, 2020 at 4:00 pm
Vancouver, British Columbia--(Newsfile Corp. - January 28, 2020) - The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) (FSE: YG3) announces subsidiary Flourish Mushroom Labs is executing on its strategy ...
- Natural Psilocybin Medicines and Training Hit the Marketon January 27, 2020 at 12:02 pm
/PRNewswire/ -- In the last two decades, the party drugs of the 1960s and beyond - LSD, ecstasy, and magic mushrooms among them - have been returning to ...
- Woman Trademarks ‘Psilocybin’ To Prevent Commercialization Of Mushroomson January 24, 2020 at 5:26 pm
“I got a lot of hate emails,” said Scarlet Ravin. “I got a lot of people threatening me when they found out I got this trademark.” Psilocybin is the active compound in psychedelic mushrooms. Sonoma ...
via Google News and Bing News